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SHORT COMMUNICATION
Tissue levels ofmatrix metalloproteinases MMP-2 and MMP-9 are related
to the overall survival of patients with gastric carcinoma
CFM Sierl, FJGM Kubben', S Ganeshl, MM Heerding', G Griffioen', R Hanemaaijer2,
JHJM van Krieken3, CBHW Lamers' and HW Verspaget'
Departments of'Gastroenterology and Hepatology and 'Pathology, University Hospital, PO Box 9600, 2300 RC Leiden; 2Gaubius
Laboratory, TNO-PG, PO Box 430, 2300 AK Leiden, The Netherlands.
Summary Proteinases are involved in tumour invasion and metastasis. Several matrix metalloproteinases
(MMPs) have been shown to be increased in various human carcinomas. We assessed the levels of MMP-2
(gelatinase A) and MMP-9 (gelatinase B) in 50 gastric carcinomas and corresponding mucosa using
quantitative gelatin zymography. Both MMP levels were significantly enhanced in gastric carcinomas compared
with adjacent mucosal tissue, showed a relatively poor intercorrelation and no relation was found with
histopathological carcinoma classifications according to Lauren, WHO and tumour-node-metastasis (TNM).
Cox's multivariate proportional hazards analyses revealed that high carcinomatous MMP values are of
prognostic significance for a poor overall survival of the patients, independent of the major clinicopathological
parameters.
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The process of carcinogenesis involves sequential breakdown
of extracellular matrix by a variety of proteolytic enzymes
(Duffy, 1992). Gelatinases, collagenases and stromelysins are
metalloproteinases (MMPs), which are able to solubilise
collagens in basement membranes and extracellular stroma
(Matrisian, 1992). This local proteolysis enables tumour cells
to penetrate normal surrounding tissue. Immunohistochem-
ical and in situ hybridisation studies in human gastrointest-
inal neoplasias have shown that these carcinomas contain
enhanced amounts of matrix metalloproteinases (McDonnell
et al., 1991; Poulsom et al., 1992; Grigioni et al., 1994). The
enhanced proteolytic capacity of tumour tissues is confirmed
by studying tissue homogenates, using quantitative methods
like activity assays, and ELISAs (Yamagata et al., 1991;
Kimura et al., 1993; Duffy et al., 1995). Some in vitro and in
vivo experiments showed that matrix metalloproteinase levels
were related to the invading and metastatic potential of
colorectal cancer (Kimura et al., 1993; Emmert-Buck et al.,
1994). Moreover, plasma levels of some MMPs were found to
be enhanced in patients with colonic cancer (Zucker et al.,
1993).
In this study we used a relatively straightforward method,
gelatin zymography, to evaluate the presence of MMP-2
(gelatinase A) and MMP-9 (gelatinase B) in stomach
carcinomas and adjacent mucosa from 50 patients, from
whom clinical and histopathological data concerning patients
and carcinomas were available. Quantitative zymography has
been shown previously to be an extremely reliable and
sensitive technique for the detection of gelatinases (Kleiner
and Stetler-Stevenson, 1994; Zucker et al., 1994). Moreover,
this method of detection distinguishes proteinases in the
proenzyme and the active form. The amounts of MMPs were
related to several types of gastric tumour staging systems,
including the classifications of Lauren, WHO and TNM. The
prognostic significance of the MMP-2 and MMP-9 levels for
the survival of patients with a gastric carcinoma was
evaluated using Cox's proportional hazards method in
univariate analysis, and also multivariately by addition to a
broad selection of established clinicopathological variables.
Patients, materials and methods
Patients
Fresh tissue was obtained from 50 patients who underwent
resection with curative intent for primary gastric cancer at the
Department of Oncologic Surgery, University Hospital
Leiden, as previously described (Ganesh et al., 1996).
Representative samples of the carcinoma and macroscopi-
cally normal mucosa, taken 5-10 cm from the tumour, were
frozen and stored at -70°C until extraction. Pathological
and histological data of the tissues were re-evaluated by one
pathologist (JvK). The patients entered the study at the date
of surgery, did not receive adjuvant (chemo) therapy, and
were clinically checked twice a year. Follow-up had to be at
least 2 years and ended in the event of death or when still
alive the last follow-up date before the common closing date
(follow-up range 0.5-81 months).
Tissue extraction and protein concentration
Tissue specimens were homogenised in 0.1 M Tris-HCl, 0.1%
(v/v) Tween 80 as described extensively previously (Sier et al.,
1991; Ganesh et al., 1994a, 1996). Protein concentrations of
the supernatants were determined by the method of Lowry et
al. (1951).
Gelatin-zymography
Presence of active and latent forms of matrix metalloprotei-
nases was analysed by zymography on 10% polyacrylamide
gels containing 2% gelatin and overnight incubation at 37°C,
as described previously (Hanemaaijer et al., 1993). Sample
volumes were adjusted to obtain a uniform protein content of
20 ig per sample. The gels were stained with Coomassie
brilliant blue R-250, dried between sheets of cellophane, and
the degree of gelatin digestion was quantified using a LKB
Ultroscan XL enhanced laser densitometer (633 nm). Two
amounts (12 and 24 jig protein, SI and S2 respectively) of an
internal standard preparation, i.e. a homogenate of a colonic
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carcinoma containing both MMP-2 and MMP-9, were
included on each gel for correction of intergel variation and
as reference for the expression in arbitrary units (AU). This
zymographic analysis was highly linear over an at least 20-
fold range (i.e. 2-40 ,g protein per sample) and was
validated for MMP-9 by an established ELISA (Bergmann
et al., 1989) in 30 diverse gastrointestinal tissue homogenates
yielding a good correlation between these assays
(0.65<r<0.77, P<0.0001).
Statistical analyses
Group means are given as mean+s.e.m. Differences between
groups were tested for significance using paired Student's t-
test with separate variance estimate if the standard deviations
were significantly different according to the f-test. Optimal
cut off analysis was performed by stepwise univariate Cox's
proportional hazards analyses. Univariate and multivariate
survival analyses were performed using Cox's proportional
hazards method (EGRET statistical package, SERC Corp.,
Seattle, WA, USA) (Cox, 1972). Overall survival curves were
constructed according to the method of Kaplan and Meier
(1958). Differences were considered significant when P<0.05.
Results
The characteristics of the 50 gastric cancer patients revealed
that most of the patients were males (38 patients, i.e. 76%)
and had died during follow-up (76%, 38/50), although the
deceased patients were not significantly older [67.2+ 1.8 years
(n =38) vs 66.0+4.5 years (n= 12)]. All the clinicopathologi-
cal parameters assessed were dichotomised as illustrated in
Table I. Subdivision according to established histological
tumour classification systems was found to have no major
prognostic relevance in this group of patients, although
overall survival decreased with increasing TNM stage [i.e. I,
43% (6/14); II, 20% (4/20); III, 17% (2/12); IV, 0% (0/4)].
Including all the other clinicopathological parameters
evaluated, only the presence of many eosinophilic cells in
Table I Univariate Cox's proportional hazards analysis of clinicopathological parameters in relation
to overall survival of patients with gastric cancer
Number of Median survival Survival Hazard
Parameter patients time (months) (%) ratio (P-value)
Gender
male vs female 38-12 16.0-13.0 26.3 -16.7 1.1 (NS)
Age (years)
<66.3 vs )66.3 (median) 25 -25 18.4-10.1 20.0-28.0 1.2 (NS)
Lauren classification
Diffuse/mixed vs intestinal 18-31 27.0- 11.3 33.3-16.1 1.6 (NS)
WHO differentiation
Well/moderately vs poorly 34- 15 15.0-27.1 14.7-40.0 0.6 (NS)
TNM
Stage 1+11 vs stage III+IV 34-16 18.3-15.0 29.4-12.5 1.3 (NS)
Localisation
Antrum vs other 23 -27 18.3-12.3 30.4- 18.5 1.6 (NS)
Diameter
A5 cm vs >5 cm 28 -22 18.0-12.5 25.0-22.7 1.1 (NS)
Eosinophils
Many vs moderate/few 7-43 4.3-16.4 0.0-27.9 0.4 (0.02)
Intestinal metaplasia in mucosa
Absent vs present 18-32 11.5-18.0 11.1 -31.3 0.5 (NS)
NS, not significant.
+ EDTA
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Figure 1 Example of the gelatin zymograms used for the MMP-2 and MMP-9 quantitation by laser densitometry, as described in
Materials and methods. Complete inhibition of the MMP activities was achieved by overnight incubation in the presence of 50mM
EDTA. Numbers indicate pairs of tissue from one patient. N, gastric mucosa; C, gastric carcinoma; S, standard (reference). MMPs:
P, pro-enzyme; A, active enzyme.
414the carcinomas was significantly associated with a worse
survival, exemplified by a shorter median survival time and a
low percentage survival of the patients (Table I).
The mean levels of matrix metalloproteinases MMP-2 and
MMP-9, as determined by EDTA-inhibitable gelatin-zymo-
graphy (Figure 1), were significantly higher in carcinomas
than in histologically confirmed tumour-free adjacent mucosa
of the stomach, irrespective of MMP type or activity state
(Table II). Of the carcinomas, 82% (41/50) contained more
total MMP-2 and 80% (40/50) contained more total MMP-9
than their corresponding mucosa, i.e. ratios higher than 1, as
illustrated in Figure 2. The enhanced amounts of MMPs in
the carcinomas were not significantly correlated to any of the
histological gastric tumour classification systems, although
the carcinomas that were superficially invasive showed the
lowest total MMP levels (MMP-2, 1.28+0.34; MMP-9,
2.49+1.18; in AU, n=4), and were similar to the mucosal
levels. The total levels of MMP-2 and MMP-9 showed a
relatively poor intercorrelation (mucosa r=0.19, NS;
carcinomas r=0.34, P=0.01). For each of the MMP
parameters in mucosa and carcinoma tissues the optimum
cut-off values were determined using Cox's proportional
hazards analyses (Table III). In mucosa a significant cut-off
value was found only for the active form of MMP-9 and
indicated that a high level was associated with a good
prognosis. In contrast, for the carcinomas, the total and the
pro-forms of MMP-2 and MMP-9, as well as the active form
of MMP-2 showed significant cut-off values revealing that
high levels indicated a poor prognosis. Representative
Kaplan-Meier curves for overall survival according to the
cut-off points for total MMP-2 and MMP-9 are shown in
Figures 3 and 4. Table III shows the hazard ratios of all the
significant MMP parameters according to Cox's proportional
Table II Levels of matrix metalloproteinases MMP-2 and MMP-9
in mucosa and carcinomas of 50 patients with gastric cancer
P-value
Mucosa Carcinoma paired t-test
MMP-2
Total 1.50±0.11 2.63±0.23 <0.001
Pro-form 1.24+0.11 1.90+0.16 <0.001
Active 0.26+0.03 0.73 +0.10 <0.001
MMP-9
Total 3.72+0.23 5.92±0.32 <0.001
Pro-form 3.18 i0.21 4.99 +0.25 <0.001
Active 0.54+0.08 0.93 +0.09 0.001
Mean ±s.e. The MMPs were quantified using gelatin-zymography
and subsequent laser densitometry. Values are expressed in arbitary
units.
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hazards analyses. For the multivariate analyses the MMP
parameters were separately evaluated by adjusting to all
clinicopathological variables as listed in Table I. All the
MMP parameters kept their prognostic significance in the
multivariate analyses.
Discussion
Several proteolytic enzymes are involved in carcinogenesis.
Various studies have shown, for instance, high concentrations
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Figure 2 Individual data of the total MMP-2 and total MMP-9
ratio, carcinoma over mucosa, of the 50 gastric cancer patients.
Dotted line indicates a ratio of 1, i.e. MMP level in carcinoma is
identical to that of the gastric mucosa.
Table III Uni- and multivariate Cox's proportional hazards analyses of MMP-2 and MMP-9 in
gastric mucosa and gastric carcinomas related to overall survival of the patients
Number Median Hazard Hazard ratio
of suvival time Survival ratio (P) (P) Parameteea patients (months) (%) univariate multivariate
Mucosa
MMP-9 active
<0.36 vs >0.36 25-25 8.4-27.4 16.0-32.0 0.4 (0.02) 0.3 (0.02)
Carcinoma
MMP-2 total
<4.00 vs >4.00 42-8 18.2-10.0 28.6-0.0 2.6 (0.02) 2.5 (0.05)
MMP-2 pro-form
<2.82 vs >2.82 42-8 18.2-10.0 28.6-0.0 2.6 (0.02) 2.9 (0.03)
MMP-2 active
<0.55 vs >0.55 27-23 27.4-10.4 37.0-8.7 2.1 (0.03) 3.1 (0.02)
MMP-9 total
<7.25 vs >7.25 35- 15 18.4- 10.1 31.4-6.7 2.0 (0.04) 2.1 (0.05)
MMP-9 pro-form
<5.75 vs >5.75 33-17 27.1-9.3 33.3-5.9 2.6 (0.006) 2.8 (0.01)
Multivariate analyses were performed by adjusting the separate MMP parameters to all
clinicopathological parameters indicated in Table II. aIn arbitary units.
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Figure 3 Kaplan-Meier overall survival curve for total MMP-2
levels in gastric carcinomas. MMP-2 values were evaluated using
gelatin zymography and subsequent laser densitometry and are
expressed in arbitrary units. High and low levels of MMP-2, cut-
off point 4.0, were determined by Cox's univariate proportional
hazards analysis. Values indicate the number of patients alive/
deceased at the end of follow-up.
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Figure 4 Kaplan-Meier overall survival curve for total MMP-9
levels in gastric carcinomas. MMP-9 values were evaluated using
gelatin-zymography and subsequent laser densitometry and are
expressed in arbitrary units. High and low levels of MMP-9, cut-
off point 7.25, were determined by Cox's univariate proportional
hazards analysis. Values indicate the number of patients alive/
deceased at the end of follow-up.
of plasminogen activators, cathepsins and matrix metallo-
proteinases in different types of human carcinomas
(McDonnell et al., 1991; Yamagata et al., 1991; Duffy,
1992; Matrisian, 1992; Poulsom et al., 1992; Kimura et al.,
1993; Zucker et al., 1993; Emmert-Buck et al., 1994; Grigioni
et al., 1994; Duffy et al., 1995). In the present study we show
that in a majority of gastric carcinomas the MMP-2 and
MMP-9 levels are significantly higher than in the correspond-
ing gastric mucosa, irrespective of the activity state of the
enzymes. Moreover, our observation that the more deeply
invasive carcinomas contain high levels of MMPs, whereas
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the superficially invasive tumours do not show more MMP
than the corresponding mucosa, is in agreement with recent
immunohistological data in which MMP-2 was found to be
higher in advanced vs early gastric tumours (Grigioni et al.,
1994). The levels of MMP-2 and MMP-9 showed a relatively
poor intercorrelation, both in gastric mucosa and in
carcinomas, suggesting an independent expression pattern
for both proteinases, which is probably related to differences
in the cellular origin of these enzymes (Matrisian, 1992), but
this was not assessed in the present study.
Recently, the evaluation in carcinomatous tissue of some
components of the plasminogen activation cascade, another
important proteolytic system in carcinogenesis, has been
found to be of significant value for the prognosis of cancer
patients (Duffy et al., 1988; Janicke et al., 1991; Hasui et al.,
1992; Ganesh et al., 1994a, and b; Nekarda et al., 1994;
Pedersen et al., 1994). Although the number ofpatients in the
present study is relatively low, the results clearly show that
high levels of MMP-2 and MMP-9 in stomach carcinomas
are associated with a poor overall survival, which has never
been reported before. The distinction between total, active
and pro-form of MMPs in our study, as one ofthe important
advantages of the zymographic analysis, seems to be
particularly useful for MMP-2. The interpretation of the
prognostic significance of MMP-9 in mucosa from patients
with a gastric carcinoma is difficult. However, high levels of
tissue-type plasminogen activator activity in normal color-
ectal and gastric mucosa were also found to be associated
with a good prognosis in colorectal and gastric cancer
patients (Ganesh et al., 1994a, and 1996).
The results of this study could have important clinical
implications. Firstly, the prognostic significance of both
MMPs in carcinomatous tissue is striking, especially in
comparison with the relatively disappointing performance of
established parameters like TNM and Lauren classification or
diameter of the carcinoma. Therefore these proteolytic
parameters may be suitable as prognosticators for the
selection of patients for adjuvant therapy. Secondly, this
study might give some rationale for therapeutic intervention
with matrix metalloproteinase inhibitors, which has recently
been demonstrated to be effective in patient-like orthotopic
human tumour models in nude mice (Naito et al., 1994;
Wang et al., 1994).
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